Piras Anna M, Maisetta Giuseppantonio, Sandreschi Stefania, Gazzarri Matteo, Bartoli Cristina, Grassi Lucia, Esin Semih, Chiellini Federica, Batoni Giovanna
Department of Chemistry and Industrial Chemistry, University of Pisa Pisa, Italy ; National Interuniversity Consortium of Materials Science and Technology, Florence Italy.
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa Pisa, Italy.
Front Microbiol. 2015 Apr 28;6:372. doi: 10.3389/fmicb.2015.00372. eCollection 2015.
Nowadays, the alarming rise in multidrug-resistant microorganisms urgently demands for suitable alternatives to current antibiotics. In this regard, antimicrobial peptides (AMPs) have received growing interest due to their broad spectrum of activities, potent antimicrobial properties, unique mechanisms of action, and low tendency to induce resistance. However, their pharmaceutical development is hampered by potential toxicity, relatively low stability and manufacturing costs. In the present study, we tested the hypothesis that the encapsulation of the frog-skin derived AMP temporin B (TB) into chitosan nanoparticles (CS-NPs) could increase peptide's antibacterial activity, while reducing its toxic potential. TB-loaded CS-NPs with good dimensional features were prepared, based on the ionotropic gelation between CS and sodium tripolyphosphate. The encapsulation efficiency of TB in the formulation was up to 75%. Release kinetic studies highlighted a linear release of the peptide from the nanocarrier, in the adopted experimental conditions. Interestingly, the encapsulation of TB in CS-NPs demonstrated to reduce significantly the peptide's cytotoxicity against mammalian cells. Additionally, the nanocarrier evidenced a sustained antibacterial action against various strains of Staphylococcus epidermidis for at least 4 days, with up to 4-log reduction in the number of viable bacteria compared to plain CS-NPs at the end of the observational period. Of note, the antimicrobial evaluation tests demonstrated that while the intrinsic antimicrobial activity of CS ensured a "burst" effect, the gradual release of TB further reduced the viable bacterial count, preventing the regrowth of the residual cells and ensuring a long-lasting antibacterial effect. The developed nanocarrier is eligible for the administration of several AMPs of therapeutic interest with physical-chemical characteristics analog to those of TB.
如今,多重耐药微生物的惊人增长迫切需要找到替代当前抗生素的合适药物。在这方面,抗菌肽(AMPs)因其广泛的活性谱、强大的抗菌特性、独特的作用机制以及较低的诱导耐药倾向而受到越来越多的关注。然而,它们的药物开发受到潜在毒性、相对较低的稳定性和制造成本的阻碍。在本研究中,我们测试了以下假设:将青蛙皮肤来源的抗菌肽天蚕素B(TB)包裹在壳聚糖纳米颗粒(CS-NPs)中可以增强该肽的抗菌活性,同时降低其潜在毒性。基于CS与三聚磷酸钠之间的离子凝胶化作用,制备了具有良好尺寸特征的负载TB的CS-NPs。该制剂中TB的包封率高达75%。释放动力学研究表明,在所采用的实验条件下,该肽从纳米载体中呈线性释放。有趣的是,TB包裹在CS-NPs中可显著降低该肽对哺乳动物细胞的细胞毒性。此外,该纳米载体对各种表皮葡萄球菌菌株表现出持续的抗菌作用,至少持续4天,在观察期结束时,与普通CS-NPs相比,活菌数量最多可减少4个对数级。值得注意的是,抗菌评估测试表明,虽然CS的固有抗菌活性确保了“爆发”效应,但TB的逐渐释放进一步降低了活菌数量,防止了残留细胞的再生,并确保了持久的抗菌效果。所开发的纳米载体适用于多种具有治疗意义的AMPs的给药,其物理化学特性与TB类似。